ALNY) disclosed on Thursday the receipt of a US new
patent under its McSwiggen
patent estate for the advancement of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection.
The company added that the US patent no. 8,618,277, or '277 patent, which includes broad, sequence-independent issued claims on compositions of chemically modified siRNA targeting HBV, was awarded by the US Patent and Trademark Office (USPTO).